Journal
BIOCHEMISTRY
Volume 55, Issue 48, Pages 6673-6684Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.biochem.6b00610
Keywords
-
Categories
Funding
- National 973 Program from the Chinese Ministry of Science and Technology [2014CB910301]
- National Institutes of Health [HL086392, GM098878, DK088057, NS094535]
- American Heart Association [12EIA8850017]
- Cancer Prevention and Research Institute of Texas [R1223]
Ask authors/readers for more resources
STEAP1, six-transmembrane epithelial antigen of prostate member 1, is strongly expressed in several types of cancer cells, particularly in prostate cancer, and inhibition of its expression reduces the rate of tumor cell proliferation. However, the physiological function of STEAP1 remains unknown. Here for the first time, we purified a mammalian (rabbit) STEAP1 at a milligram level, permitting its high quality biochemical and biophysical characterizations. We found that STEAP1 likely assembles as a homotrimer and forms a heterotrimer when co-expressed with STEAP2. Each STEAP1 protomer binds one heme prosthetic group that is mainly low-spin with a pair of histidine axial ligands, with small portions of high-spin and P450-type heme. In its ferrous state, STEAP1 is capable of reducing transition metal ion complexes of Fe3+ and Cu2+. Ferrous STEAP1 also reacts readily with O-2 through an outer sphere redox mechanism. Kinetics with all three substrates are biphasic with similar to 80 and similar to 20% for the fast and slow phases, respectively, in line with its heme heterogeneity. STEAP1 retained a low level of bound FAD during purification, and the binding equilibrium constant, K-D, was similar to 30 mu M. These results highlight STEAP as a novel metal reductase and superoxide synthase and establish a solid basis for further research into understanding how STEAP1 activities may affect cancer progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available